secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jasper Therapeutics, Inc. (JSPR)
CIK:        0001788028
Form:       8-K
Filed at:   2023-08-11T23:59:59+00:00
Accession:  0001213900-23-066233
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jasper Therapeutics Q2 2023 net loss $16.1M; cash $115.8M; first patient dosed in LR-MDS trial
--------------------------------------------------------------------------------

- Net loss of $16.1M for Q2 2023 vs $10.4M in Q2 2022; R&D expenses increased to $13.3M from $8.1M.
- Cash and cash equivalents $115.8M as of June 30, 2023, up from $38.3M at Dec 31, 2022; runway through 2024.
- First patient dosed in Phase 1 trial of briquilimab for lower-risk MDS (LR-MDS) at Moffitt Cancer Center.
- Key appointments: Scott Brun to Board, Edwin Tucker as CMO, and others to Scientific Advisory Board and leadership.
- Company plans to initiate chronic spontaneous urticaria study in coming months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1788028/000121390023066233/0001213900-23-066233-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1788028/000121390023066233/ea183229-8k_jasperthera.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-066233

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer